Key facts
- This page summarizes Carl Anthony Evans's Form 4 filing for CNS Pharmaceuticals, Inc. (CNSP).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 10 Apr 2024, 21:52.
Carl Anthony Evans - 08 Apr 2024 Form 4 Insider Report for CNS Pharmaceuticals, Inc. (CNSP)
- Reporting relationship
- Director
- Issuer ticker
- CNSP
- Reported as of
- 08 Apr 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 10 Apr 2024, 21:52:02 UTC
- Prior SEC filing
- 06 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christopher Downs, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Carl Anthony Evans filed Form 4 for CNS Pharmaceuticals, Inc. (CNSP) on 10 Apr 2024.
Change
- Previous filing in this sequence was filed on 06 Feb 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CNSP
transaction
Derivative
Option to purchase common stock
Award
- Transaction value
- Shares
- +17,500
- Change %
- +16%
- Price
- Shares after
- 129,594
- Date
- 08 Apr 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 17,500
- Exercise price
- $0.2586
- Footnotes
- F1, F2
CNSP
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- Shares
- +17,500
- Change %
- +14%
- Price
- Shares after
- 147,094
- Date
- 08 Apr 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 17,500
- Exercise price
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date.
Footnote F2
The awards were issued in connection with the reporting person's Board of Director services to the Company.
Footnote F3
Each restricted stock unit represents a contingent right to receive one share of the Company common stock.